Non-Rhabdomyosarcoma - Pipeline Review, H2 2012

Global Markets Direct, August 2012, Pages: 37

Non-Rhabdomyosarcoma – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Non-Rhabdomyosarcoma - Pipeline Review, H2 2012', provides an overview of the Non-Rhabdomyosarcoma therapeutic pipeline. This report provides information on the therapeutic development for Non-Rhabdomyosarcoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Non-Rhabdomyosarcoma. 'Non-Rhabdomyosarcoma - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Non-Rhabdomyosarcoma.
- A review of the Non-Rhabdomyosarcoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Non-Rhabdomyosarcoma pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Non-Rhabdomyosarcoma.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Non-Rhabdomyosarcoma pipeline depth and focus of Non-Rhabdomyosarcoma therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Non-Rhabdomyosarcoma Therapeutic Products under Development, Key Players in Non-Rhabdomyosarcoma Therapeutics, Non-Rhabdomyosarcoma Pipeline Overview, Non-Rhabdomyosarcoma Pipeline, Non-Rhabdomyosarcoma Pipeline Assessment

2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Non-Rhabdomyosarcoma Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Non-Rhabdomyosarcoma 7
Non-Rhabdomyosarcoma Therapeutics under Development by Companies 9
Non-Rhabdomyosarcoma Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 12
Comparative Analysis 12
Mid Clinical Stage Products 13
Comparative Analysis 13
Early Clinical Stage Products 14
Comparative Analysis 14
Non-Rhabdomyosarcoma Therapeutics – Products under Development by Companies 15
Non-Rhabdomyosarcoma Therapeutics – Products under Investigation by Universities/Institutes 16
Companies Involved in Non-Rhabdomyosarcoma Therapeutics Development 17
Pfizer Inc. 17
Non-Rhabdomyosarcoma – Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Combination Products 19
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Drug Profiles 24
Glivac - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Gemcitabine + Trabectedin - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
PD-0332991 - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Rosiglitazone - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Pazopanib - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Doxorubicin + Ifosfamide + Radiation Therapy - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Non-Rhabdomyosarcoma Therapeutics – Discontinued Products 33
Non-Rhabdomyosarcoma Therapeutics - Dormant Products 34
Non-Rhabdomyosarcoma – Product Development Milestones 35
Featured News & Press Releases 35
Jun 26, 2012: BioSpecifics Initiates XIAFLEX Phase II Trial For Human Lipomas 35
Appendix 36
Methodology 36
Coverage 36
Secondary Research 36
Primary Research 36
Expert Panel Validation 36
Contact Us 37
Disclaimer 37

List of Tables
Number of Products Under Development for Non-Rhabdomyosarcoma, H2 2012 7
Products under Development for Non-Rhabdomyosarcoma – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 11
Comparative Analysis by Late Stage Development, H2 2012 12
Comparative Analysis by Mid Clinical Stage Development, H2 2012 13
Comparative Analysis by Early Clinical Stage Development, H2 2012 14
Products under Development by Companies, H2 2012 15
Products under Investigation by Universities/Institutes, H2 2012 16
Pfizer Inc., H2 2012 17
Assessment by Monotherapy Products, H2 2012 18
Assessment by Combination Products, H2 2012 19
Assessment by Stage and Route of Administration, H2 2012 21
Assessment by Stage and Molecule Type, H2 2012 23
Non-Rhabdomyosarcoma Therapeutics – Discontinued Products 33
Non-Rhabdomyosarcoma Therapeutics – Dormant Products 34

List of Figures
Number of Products under Development for Non-Rhabdomyosarcoma, H2 2012 7
Products under Development for Non-Rhabdomyosarcoma – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Late Stage Products, H2 2012 12
Mid Clinical Stage Products, H2 2012 13
Early Clinical Stage Products, H2 2012 14
Assessment by Monotherapy Products, H2 2012 18
Assessment by Combination Products, H2 2012 19
Assessment by Route of Administration, H2 2012 20
Assessment by Stage and Route of Administration, H2 2012 21
Assessment by Molecule Type, H2 2012 22
Assessment by Stage and Molecule Type, H2 2012 23

Customers who bought this item also bought

• Nausea – Pipeline Review, H1 2013
• Drug Addiction – Pipeline Review, H1 2013
• Sleep Disorders – Pipeline Review, H1 2013
• Lung Infections – Pipeline Review, H1 2013
• Smoking Cessation – Pipeline Review, H1 2013
• Peanut Allergy – Pipeline Review, H1 2013
• Measles – Pipeline Review, H1 2013
• Bone Disorders – Pipeline Review, H1 2013
• Liver Transplantation – Pipeline Review, H1 2013
• HIV / AIDS – Pipeline Review, H1 2013